Chapter 74 Dean Zhou: It’s up to you now!
The news that Qingshan Pharmaceutical’s new drug code-named “QS-001” has entered the second phase of clinical trials has also reached Baidu Tieba - Hepatitis B Bar.
Hepatitis B Bar can be said to be the Tieba with the largest number of active patients in the entire Tieba.
The vast majority of patients here have suffered from hepatitis B for ten or twenty years, and a very small number have even lived with it for thirty years.
As they said, they have experienced dozens of drugs to treat hepatitis B over the years and heard about various new drugs from countless pharmaceutical companies.
Even the country began to propose a cure for hepatitis B in 2010, but fifteen years later, hepatitis B is still there.
So, even if the country restarts the "Starlight Project" again, and even if new drugs are added to the "Starlight Project" one after another, the enthusiasm of the entire Tieba patients for the "Starlight Project" is still very low.
Even cold.
Huang Yi is the owner of the hepatitis B forum. Although the discussion in the forum is very low, he will still take the time to upload the latest information from various pharmaceutical companies to the forum whenever there is news.
He has always believed that as long as pharmaceutical companies are developing hepatitis B drugs, there is still hope for hepatitis B patients.
But as usual, after he posted [Qingshan Pharmaceutical's latest drug "QS-001" officially entered the second clinical phase], although the concept of "cytotoxicity" proposed by this drug was very novel, it was enough to wait. Within an hour,
it obviously had hundreds of views, but except for advertisements about watching movies and robots, there were no replies to the post.
This is the indifference that can be felt personally.
“Hey!”
Huang Yi sighed helplessly.
...
The indifference of the hepatitis B bar seems to have also spread to the second phase of clinical recruitment of "Ecofovir". With Zhang Yang increasing the trial subsidy to 20,000 yuan, many patients have indeed been attracted to come for consultation. .
However, due to the fear of cytotoxicity and liver toxicity, only five patients actually signed the informed consent form after a week and were willing to participate in the trial.
Zhang Yang couldn't help but frowned while looking at the data in his hand, and had already begun to think about whether to continue to increase the trial subsidy fee.
According to the current pace of recruiting five people a week, this speed is too slow. .
But just when he was thinking about it,
before he was anxious, Director Zhou of the Third People's Hospital of Chengdu became anxious instead.
“This Zhang Yang doesn’t even tell me when he has difficulties. It’s so uninteresting!”
Dean Zhou slammed the table and said, “Ecofuvir” at Qingshan Pharmaceutical "A week after the second clinical phase was carried out, he finally learned about the current predicament of Qingshan Pharmaceutical from Director Feng Gang.
After a while, looking at the surprised Feng Gang in front of him, he ordered:
"Director Feng, fortunately you reminded me in time. I will immediately notify all the doctors and nurses in the Department of Infectious Diseases to hold a meeting."
With an order,
At five o'clock in the afternoon, Dean Zhou came to the hospital in person Department of Infectious Diseases Conference Room.
“To make a long story short, a new hepatitis B cure drug ‘QS-001’ from Tsingshan Pharmaceutical, a well-known domestic pharmaceutical company, has recently launched a phase II clinical trial in our hospital. I believe everyone knows about it, right?”
Everyone nodded slightly.
With the launch of the national "Starlight Project", although the Department of Infectious Diseases of Third Person Hospital is not outstanding, it has also received clinical trial tasks for two or three new drugs.
However,
Deputy Director Feng Gang actually said hello to this new drug in private before, hoping that suitable hepatitis B patients would be recommended to participate in the trial of this new drug.
No Thinking of Dean Zhou meeting in person to mention this matter... Just as everyone was thinking wildly, Dean Zhou continued:
"Now that everyone knows, why is it that after a week, Qingshan Pharmaceutical has even increased the trial subsidy by 20,000 yuan, and why are there still only five patients participating?"
After the words fell, everyone was stunned, even infectious diseases Chen Wen, the director of the department, couldn't help but flash a hint of surprise.
Why is Dean Zhou suddenly so concerned about the development progress of a new drug?
As for why Tsingshan Pharmaceutical’s new drugs are being promoted slowly, everyone knows very well. Tsingshan Pharmaceutical’s “QS-001” is cytotoxic, and patients have strong resistance. It is really very difficult!
At this moment, Dean Zhou’s voice sounded again.
"I know that this new drug is cytotoxic, but... we are all professional doctors. If the Ethics Committee can allow this new drug to enter the second phase of clinical trials, it means that the toxicity is controllable. The risk labeling is just to let patients have the right to know!"
“Moreover, the purpose of cytotoxicity is to kill the hepatitis B virus, which means it is possible to cure it Hepatitis B, I believe if you explain it well, there will be hepatitis B patients who are willing to try it!”
Speaking of this, he coughed heavily:
“I won’t say more. Make a request, Director Chen, and the head nurse should take note of it.”
Director Chen Wen and the head nurse sat upright instantly.
"Starting from today, all patients with hepatitis B, whether inpatients or outpatients, must be recommended to participate in the trial of this new drug. In short, we fully support the second phase clinical trial of QS-001 by Qingshan Pharmaceutical."
“Of course , Don’t let everyone work in vain, the financial department will note that for every patient who participates in the trial, the department’s overall performance bonus will be increased by one thousand yuan, and will be paid the next month.”
The conference room was silent, and after just three seconds, The quiet conference room suddenly burst into heated discussion!
Dean Zhou saw that the doctors and nurses in the audience were aroused with enthusiasm, and a smile appeared at the corner of his mouth.
Remembering that Zhang Yang still kept his promise and reached an agreement with himself despite the entreaties of many well-known hospitals. At this time, it can be regarded as repaying Zhang Yang's original favor.
"Zhang Yang, I said at the beginning that I am determined to be your friend!"
"Now, I have done my best, and the rest is up to you!"
>With the full support of Dean Zhou, the doctors and nurses in the general department had an in-depth understanding of "Ecofuvir" that afternoon.
After this understanding, I discovered that
yes, "Ecofovir" is indeed cytotoxic,
But as Dean Zhou said, since it can reach the second phase of clinical trials, it proves that the toxicity is controllable, and the reason for the cytotoxicity is to kill the hepatitis B virus.
As for whether hepatitis B can be cured, everyone is hesitant. After all, is there any drug that can cure hepatitis B?
Early the next morning, a young patient appeared in the field of vision of department director Chen Wen.
Xu Bo, male, 32 years old, born in 1992.
Hepatitis B is different from other departments. As a chronic infectious disease, once hepatitis B patients are antiviral (taking antiviral drugs), they need to take long-term medication and undergo regular reexaminations.
Generally speaking, hepatitis B patients need to undergo a re-examination every three months or up to half a year. Therefore, most patients will choose a fixed doctor for long-term treatment.
The reason is also very simple. Doctors who have followed for a long time often have a better understanding of their own conditions.
Xu Bo is a long-term patient of Director Chen Wen.
Two years ago, Xu Bo truly realized the harm caused by hepatitis B for the first time and began to receive formal antiviral treatment.
After taking medication for a year, he finally decided to try interferon.
(End of this chapter)